biospecimen banks

CPDR Patient Education Program

Industry-Sponsored Clinical Trials and Projects

The CRC maintains a comprehensive portfolio of both investigator-initiated and industrysponsored clinical trials that cover the entire patient's "life cycle." Some of the trials, though industry sponsored, were investigator-initiated trials for which a proposal was submitted by CPDR to obtain funding. There are two types of these studies:

  • One is when we approach the industry with a proposal and request funding under a collaborative type of agreement; the ownership and control remains with CPDR but costs are supported by the company. One example of this is the CPDR Prostate Cancer Quality of Life Study that has been ongoing since 2003 and has a current enrollment of more 1,600 men. This study is a unique asset to the program in that it looks at patient-reported outcomes; however, it is a very costly endeavor due to its labor intensiveness. The study includes administration of the EPIC questionnaire along with the SF-36v2® health questionnaire to men newly diagnosed with prostate cancer at baseline (before treatment), and at eight other time points subsequent to their treatment for three years. After submission of a proposal to GlaxoSmithKline, it was accepted by the company for funding on a year-to-year basis and has thus far received approval for three years of funding.

  • The other type of study is to take an idea to a company for another application or therapeutic target using that company's existing technology. This approach usually results in work being conducted under a traditional clinical trial agreement where CPDR conducts the study, is reimbursed for the time spent working on the trial, and the data are supplied to the company who uses their resources for analysis.

  • All trials and projects are carried out with full approval of the respective IRBs.


Current Clinical Trials

1. A Multicenter Clinical Study of the Sonablate®500 for the Treatment of Locally Recurrent Prostate Cancer With HIFU - Click Here for Information on the Trial

2. Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer
Click Here for Information on the Trial

3. - A Phase 3 Efficacy Study of a Recombinant Vaccinia Virus Vaccine to Treat Metastatic Prostate Cancer
Click Here for Information on the Trial



CPDR Distinguished Guest Speaker

Dr. Annette Fenner

Chief Editor
Nature Reviews Urology

Presentation: "Editor’s Insights – the Nature of Urology"

Annette Fenner studied at Imperial College London, where she completed her medical degree and intercalated a BSc in Endocrinology and PhD in Reproductive Biology. During her PhD, she worked on hypothalamic peptides in the control of reproduction, with a particular focus on the role of kisspeptins. Bringing with her an interest in the field of sexual medicine, she joined the Nature Reviews Urology team as an Associate Editor in 2010, and was promoted to Chief Editor in 2011.

Date: 30 November 2015
Time: 11:00 AM - 12:00 PM
Location: CPDR Rockville, MD


WRNMMC UsToo! Newsletter

Read the November 2015 WRNMMC UsToo! Newsletter

Go to WRNMMC UsToo! Newsletter Archive


July 20, 2015

CPDR's GHI publication is featured in the latest MDLinx "Best of Oncology"


April 21, 2014

Biological and Genomic Differences of ERG Oncoprotein-Stratified Prostate Cancers from African and Caucasian Americans